Home › Compare › UHOIF vs ABBV
UHOIF yields 1.97% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, UHOIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of UHOIF + ABBV for your $10,000?
Ushio Inc. produces and sells light application products, industrial equipment, and other products in Japan, rest of Asia, Europe, North America, and internationally. The company offers laser diodes, LED chips/packages, ultraviolet (UV) lamps, xenon lamps, halogen lamp heaters, and halogen heaters. It also provides lighting for general illumination, architecture and landscape, marine applications, and plant growth applications, as well as lamps for data projectors and LED lamps for illumination. In addition, the company offers light source units, excimer lamps and irradiation units, exposure units, illumination light sources, fishing lamps, and warning lights, as well as lighting for security applications and UV-LED for printing UniJet series. Further, it provides lithography tools and aligners, cleaning and modification systems, UV curing systems, measurement equipment, photoheating equipment, laboratory instruments, environment and sanitation related equipment, and imaging and illumination systems. Additionally, the company offers power supply repair services, power supplies, plastic injection-molding machines, mold protection devices, joints and tubing, plastic materials, factory automation products, sound-systems, and cinema servers. Ushio Inc. was incorporated in 1949 and is headquartered in Tokyo, Japan.
Full UHOIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.